Novo Nordisk experienced a notable upward trajectory driven primarily by bullish Wall Street research coverage. A major investment bank raised its price target and revised higher its sales and earnings projections for the company through 2026 and beyond. Wall Street analysts highlighted stronger-than-expected international adoption of Wegovy, limited generic erosion threats for Ozempic, and favorable second-quarter U.S. gross-to-net price adjustments as key catalysts driving the upward revisions in long-term financial forecasts.

The positive sentiment is further reinforced by the fundamental resilience of Novo Nordisk’s core GLP-1 obesity and diabetes therapies. Following better-than-expected second-quarter financial results, momentum…